Tenofovir alafenamide fumarate therapy in subjects with positive HBV-DNA and normal levels of alanine transaminase: a study protocol for a randomised controlled trial
Introduction The current clinical guidelines do not recommend antiviral therapy for subjects with positive hepatitis B virus (HBV)-DNA and normal alanine transaminase (ALT). In this study, we will assess the safety and efficacy of tenofovir alafenamide fumarate (TAF) in the treatment of adults with...
Saved in:
| Main Authors: | Lu Wang, Ying Zhang, Xuejun Li, Lina Wu, Jing Lai, Xiang Zhu, Chan Xie |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-08-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/11/8/e048410.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Reply to correspondence on “Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide”
by: Pin-Nan Cheng, et al.
Published: (2024-10-01) -
Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
by: Shenglong Lin, et al.
Published: (2024-11-01) -
Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study
by: Ping‐Feng Wu, et al.
Published: (2024-12-01) -
Long-term efficacy and safety of tenofovir alafenamide, tenofovir disoproxil fumarate, and entecavir in treating hepatitis B virus-related acute-on-chronic liver failure: A 144-week data analysis
by: Yeqiong Zhang, et al.
Published: (2024-12-01) -
Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States
by: Bruno Emond, et al.
Published: (2022-02-01)